Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

36.27 -0.38 (-1.02%)
Streaming Delayed Price Updated: 1:08 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apogee Therapeutics, Inc. - Common Stock

Why Is Apogee Therapeutics Stock Trading Higher On Monday?
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent. 
Via Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024
APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024
APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter
Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors. 
Via InvestorPlace
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023
APGE stock results show that Apogee Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded down 0.64% to 38,741.00 while the NASDAQ fell 1.64% to 15,942.27. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday?
Apogee Therapeutics unveils promising Phase 1 data for APG777, a lead candidate for atopic dermatitis treatment. Interim results show sustained biomarker inhibition and favorable safety profile. Phase... 
Via Benzinga
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Dips Over 100 Points; Target Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.33% to 38,861.95 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome
IPO stock Apogee eyed new highs Tuesday after its developmental inflammation treatment beat trial study objectives. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
Apogee, Sagimet Debut This Week In First Big IPOs Of Summer
Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.